STOCK TITAN

Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S. Fauci, MD, Director NIAID January 25-27, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Atossa Therapeutics (Nasdaq:ATOS) announced that Dr. Steven C. Quay will participate in the 2021 Precision Medicine World Conference, focusing on the development of new SARS-CoV-2 therapeutics. The event occurs virtually from January 25-27, 2021, with Dr. Quay's panel scheduled for January 26 at 11:30 AM PST. The conference highlights advancements in precision medicine and features notable speakers, including Dr. Anthony S. Fauci, the Director of the U.S. National Institute of Allergy and Infectious Diseases.

Positive
  • None.
Negative
  • None.

SEATTLE, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced that Dr. Steven C. Quay, President and CEO, will speak as a panelist at the 2021 Precision Medicine World Conference “21st Century Precision Medicine in the Age of COVID-19”

to be held virtually January 25-27, 2021.

The panel topic is “Development of New SARS-CoV-2 Therapeutics.” The panel begins at 11:30 am PST on January 26, 2021.

Dr. Anthony S. Fauci will be the spotlight speaker of the event. Dr. Fauci is the Director of the U.S. National Institute of Allergy and Infectious Diseases and Chief Medical Advisor to the President.

The Precision Medicine World Conference, or PMWC, is the largest, original forum for precision medicine. PMWC is an independent conference that attracts recognized authorities and experts across healthcare and biotechnology sectors. The conference showcases practical content that helps close the knowledge gap between different sectors, thereby catalyzing cross-functional collaboration to further adoption of personalized medicine in the clinic.

Additional information about PMWC and how to register can be found at https://www.pmwcintl.com/covid/.

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. For more information, please visit www.atossatherapeutics.com.

Forward-Looking Statements Disclaimer Statement

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering, the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Company Contact:
Atossa Therapeutics, Inc.
Kyle Guse, CFO and General Counsel
Office: 866 893-4927
kyle.guse@atossainc.com

Investor Relations Contact:
Core IR
Office:(516) 222-2560
ir@atossainc.com


FAQ

What is the significance of Atossa Therapeutics' participation in the PMWC 2021?

Atossa Therapeutics' involvement in the PMWC 2021 highlights its commitment to addressing COVID-19 and developing innovative therapeutics, showcasing its expertise in precision medicine.

When is Dr. Steven C. Quay speaking at the PMWC 2021?

Dr. Steven C. Quay is scheduled to speak on January 26, 2021, at 11:30 AM PST during the PMWC 2021.

Who is the spotlight speaker at PMWC 2021?

Dr. Anthony S. Fauci will be the spotlight speaker at the 2021 Precision Medicine World Conference.

What is the focus of the panel Dr. Quay will join at PMWC 2021?

The panel Dr. Quay will join focuses on the 'Development of New SARS-CoV-2 Therapeutics.'

Where can I register for PMWC 2021?

Registration for PMWC 2021 can be completed on the official PMWC website.

Atossa Therapeutics, Inc.

NASDAQ:ATOS

ATOS Rankings

ATOS Latest News

ATOS Stock Data

184.36M
125.76M
0.06%
27.47%
10.28%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SEATTLE